Candel Therapeutics Investor Deck Shows Extended Prostate Cancer Data and Q4 2026 BLA Filing Plan
CADL has more than doubled off its 52-week low of $4.35.
Summary
Candel Therapeutics furnished an investor presentation with extended Phase 3 prostate cancer data showing durable benefit for aglatimagene and confirmed a Q4 2026 BLA filing plan.
Key Events · Product Development and Regulatory · CADL
-
Extended Phase 3 Prostate Cancer Data
Updated data cutoff of March 15, 2026 shows aglatimagene plus standard of care improved prostate cancer-specific disease-free survival by 39% versus placebo (HR=0.61, 95% CI 0.44-0.85, p=0.0031) after median follow-up of 58 months.
-
Q4 2026 BLA Filing Planned
The presentation confirms Candel expects to submit a Biologics License Application for aglatimagene in intermediate- to high-risk localized prostate cancer in Q4 2026.
-
Phase 3 NSCLC Trial Initiation
A global Phase 3 trial of aglatimagene plus pembrolizumab in stage IV non-squamous NSCLC patients with progressive disease is planned for 2026, with approximately 500 patients across ~150 sites.
-
Phase 2a NSCLC Survival Data
Aglatimagene showed median overall survival of 25.4 months in per-protocol NSCLC patients with inadequate response to checkpoint inhibitors, versus 9.8-11.8 months for historical standard-of-care chemotherapy controls.
Analysis · CADL · Life Sciences
Candel Therapeutics furnished an updated investor presentation under Regulation FD that includes extended follow-up data from its pivotal Phase 3 prostate cancer trial for aglatimagene besadenovec. The new data cutoff of March 15, 2026 shows a 39% improvement in prostate cancer-specific disease-free survival (HR=0.61, p=0.0031) after a median follow-up of 58 months, reinforcing the primary endpoint already reported. The deck also confirms the company expects to file its Biologics License Application in Q4 2026, a near-term regulatory milestone that could transform Candel from a clinical-stage to a commercial-stage company. With $201.6 million in cash providing runway into Q1 2028, the company has the balance sheet to reach this catalyst without immediate dilution.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 30% of the 1972 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CADL was trading at $12.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $931.2M. The 52-week trading range was $4.35 to $14.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.